Furthermore, a pre-clinical study has suggested, due to the immunosuppressive nature of the TME, a combination of different immunotherapies could be considered as a promising therapeutic approach to significantly enhance the anti-tumour activity of ErbB-targeted CAR-T cells for the treatment of HNSCC (2). The gene discussed is EGFR; the disease is neoplasm.